Regulating cell-based regenerative medicine: the challenges ahead-Reference-Cited by-同舟云学术

Regulating cell-based regenerative medicine: the challenges ahead

Published:2014-01 Issue:1 Volume:9 Page:81-87
ISSN:1746-0751
Container-title:Regenerative Medicine
language:en
Short-container-title:Regenerative Medicine

Author:

Ali Robin R¹,Hollander Anthony P²,Kemp Paul³,Webster Andrew⁴,Wilkins Martin R⁵

Affiliation:

1. UCL Institute of Ophthalmology, Bath St, London EC1V 9EL, UK

2. University of Bristol, School of Cellular & Molecular Medicine, Medical Sciences Building, University of Bristol, University Walk, Clifton, Bristol BS8 1TD, UK

3. Intercytex, Core Technology Facility, 46 Grafton Street, Manchester M13 9NT, UK

4. University of York, Heslington, York YO10 5DD, UK.

5. Experimental Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK

Abstract

Those working in the regenerative medicine field currently face numerous regulatory and related challenges. This Perspective captures some of the key ideas of a UK-based working group drawn from academic, clinical and industrial communities and also identifies some key steps that should be taken in the UK and elsewhere to address these challenges.

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/rme.13.78

Reference12 articles.

1. House of Lords – Science and Technology Committee.Regenerative Medicine Report, Science and Technology Committee, HL Paper 23. The Stationery Office, London, UK (2013).

2. MastroeniM, Mittra J, Tait, J.Methodology for the Analysis of Life Science Innovation Systems (ALSIS) and its Application to Three Case Studies.Innogen, Edinburgh, UK (2012)

3. Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells

4. Traveling Across Borders—The Pitfalls of Clinical Trial Regulation and Stem Cell Exceptionalism

5. EMA – Committee for Advanced Therapies.CAT-Interested Parties (IPs) Focus Groups. A New Model for a Fruitful Interaction Between CAT and its Stakeholders, Stakeholder Workshop.EMA, London, UK (2012).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Framing regenerative medicine: culturally specific stories of an emerging technoscience;BioSocieties;2021-06-16

2. Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness;BMC Cancer;2020-07-31

3. Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product;Journal of Immunotherapy;2018-11

4. Distributive justice and regenerative medicine;Regenerative Medicine;2017-10

5. Regenerative medicine and responsible research and innovation: proposals for a responsible acceleration to the clinic;Regenerative Medicine;2017-10